<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567264</url>
  </required_header>
  <id_info>
    <org_study_id>EOC.NEUUR.2002</org_study_id>
    <nct_id>NCT04567264</nct_id>
  </id_info>
  <brief_title>Wireless, Implantable Tibial Nerve Stimulator System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis</brief_title>
  <acronym>Stimrouter</acronym>
  <official_title>Prospective Single Centre Trial of Percutaneous Tibial Nerve Stimulation With the Implantable StimRouter Neuromodulation System for the Treatment of Refractory Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiara Zecca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ABREOC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of lower urinary tract symptoms (LUTS) in patients with multiple sclerosis (MS)&#xD;
      increases with disease duration. Current management of urinary clinical symptoms in MS is&#xD;
      mainly conservative. Its long-term outcome is often poor because of the progressive disease&#xD;
      course and the treatment related side effects. Alternative therapeutic options are botulinum&#xD;
      toxin injections, electrical stimulation of dorsal penile/clitoral nerve, and sacral nerve&#xD;
      modulation. Posterior tibial nerve stimulation (PTNS) is a second minimally invasive method&#xD;
      of electrical stimulation. Multiple benefits may derive from the development and validation&#xD;
      of a dedicated protocol of a new self-activated neuromodulation therapy, which may improve&#xD;
      therapy compliance/effectiveness, quality of life and social life in MS patients with&#xD;
      refractory LUTS. Furthermore, it may contribute to reduce outpatient visits, health costs and&#xD;
      work absenteeism.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, interventional, single center</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bladder volume</measure>
    <time_frame>6 months</time_frame>
    <description>filling volume at the time of the first uninhibited detrusor contraction during cystometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cystometric capacity (mL)</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance (ml/cmH20)</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum detrusor pressure (cmH20) during storage phase</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum detrusor pressure (cmH20) during voiding phase</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voided volume (mL)</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate (mL/s)</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post void residual</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic floor electromyographic activity (normal/detrusor sphincter dyssynergia/non-relaxing pelvic floor)</measure>
    <time_frame>6 months</time_frame>
    <description>Video-urodynamic parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of voids/day</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume voided/void</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of leaks per day</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of urgency prior to void</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CISC through the day</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual urine volume</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>3-day voiding diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Quality of Life-54 (MSQOL-54)</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>54 items, two summary scores: physical health and mental health, range 0-100, a higher score indicates a better quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over active bladder questionnaire (OAB)</measure>
    <time_frame>3, 4.5, 6 months</time_frame>
    <description>Symptom severity of OAB range 6-36, higher score values indicate greater symptom severity or bother, lower scores indicate minimal symptom severity.&#xD;
Health related quality of life (HRQL) subscales (coping, sleep, and social), range 13-78, Higher scores indicate better HRQL.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>With stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of device electrodes subcutaneous in lower tibia area; stimulation of posterior tibial nerves.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>StimRouter®, Self-activated and self-controlled neuromodulation device (Bioness Inc, CE0086).</intervention_name>
    <description>Regimen 1 (weeks 0-12): one stimulation every 2 days, for a duration of 30 minutes each.&#xD;
Regimen 2 (weeks 12-24): Three stimulation treatments per week, for a duration of 30 minutes each.</description>
    <arm_group_label>With stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 - 80;&#xD;
&#xD;
          2. Diagnosis of multiple sclerosis according to McDonald [20];&#xD;
&#xD;
          3. Clinical stability over the past 6 months (no relapses and no disability progression,&#xD;
             defined as worsening of ≥1 point in the EDSS score if reference EDSS is ≤5.5, and ≥0.5&#xD;
             points if reference EDSS is&gt;5.5);&#xD;
&#xD;
          4. One or more of: urinary frequency greater than 8 times/24 hours, urinary urge&#xD;
             incontinence at least 2 episodes in 24 hours on 3-day voiding diary;&#xD;
&#xD;
          5. Urodynamic diagnosis of detrusor over-activity (DOA)and / or detrusor-sphincter&#xD;
             dyssynergia (DSD);&#xD;
&#xD;
          6. Previous failure of conservative treatments (challenge over ≥6 months) i.e. lifestyle&#xD;
             modification-fluid consumption, behavioral modification, and pharmacological therapy&#xD;
             and stable OAB medications for at least 30 days;&#xD;
&#xD;
          7. No pharmacological treatment of overactive bladder (antimuscarinics and beta-3&#xD;
             agonists) for 2 weeks prior to screening;&#xD;
&#xD;
          8. Positive response to ongoing PTNS treatment defined as ≥50% reduction in urinary&#xD;
             frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding&#xD;
             frequency (&lt;8 voids/day), based on retrospective diary review (treatment compliant and&#xD;
             non-compliant patients) or PTNS treatment naïve able to sense tibial nerve stimulation&#xD;
             (to be tested with TENS exam).&#xD;
&#xD;
          9. Competent sphincter mechanism and normally functioning upper urinary tract;&#xD;
&#xD;
         10. Leg circumference in the range of 20-30 cm at implantation site;&#xD;
&#xD;
         11. No contraindications for surgical intervention (e.g. being immunocompetent, no&#xD;
             anticoagulant treatment, no current infection);&#xD;
&#xD;
         12. For female patients: using effective contraceptive methods;&#xD;
&#xD;
         13. Ability to comply with study requirements;&#xD;
&#xD;
         14. Having provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous participation in another study with any investigational drug or device within&#xD;
             the past 90 days;&#xD;
&#xD;
          2. Any metal implant in the area of StimRouter lead implantation site;&#xD;
&#xD;
          3. Anatomical defects that preclude use of the device;&#xD;
&#xD;
          4. Treatment with botulinum toxin injections, urinary incontinence surgery or&#xD;
             implantation of artificial graft material, spinal or genitourinary surgery,&#xD;
             abdominoperineal resection of the rectum or radical hysterectomy (female)/&#xD;
             prostatectomy (male) within the last 6 months;&#xD;
&#xD;
          5. Previous treatment with sacral neuromodulation;&#xD;
&#xD;
          6. Diagnosis of pelvic pain disorders, stress incontinence, current urinary tract&#xD;
             infection, urinary stone and/or urinary tract malignancy; cystocele, enterocele or&#xD;
             rectocele of grade 3 or 4;&#xD;
&#xD;
          7. Critical limb ischemia;&#xD;
&#xD;
          8. Previous or current pelvic radiotherapy and/or chemotherapy;&#xD;
&#xD;
          9. Severe uncontrolled diabetes;&#xD;
&#xD;
         10. Being prone to excessive bleeding;&#xD;
&#xD;
         11. Having a pacemaker or implantable defibrillator or other neural stimulation systems;&#xD;
&#xD;
         12. Exposure to diathermy or electrocautery;&#xD;
&#xD;
         13. Clinically significant peripheral neuropathy;&#xD;
&#xD;
         14. Neutropenic or immune compromised;&#xD;
&#xD;
         15. Pelvic radio- and/or chemotherapy;&#xD;
&#xD;
         16. Morbid obesity (BMI &gt;40);&#xD;
&#xD;
         17. Pregnant or lactating women, or women planning a pregnancy during the study, &lt;9 months&#xD;
             post-partum;&#xD;
&#xD;
         18. Male: alpha-blocker for benign prostatic hyperplasia;&#xD;
&#xD;
         19. Allergy to local anesthetic or adhesive;&#xD;
&#xD;
         20. Life expectancy &lt;1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chiara Zecca, MD</last_name>
    <phone>+41 91 811 6921</phone>
    <email>chiara.zecca@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudio Gobbi, MD</last_name>
    <phone>+41 91 811 6921</phone>
    <email>claudio.gobbi@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6903</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Zecca, MD</last_name>
      <phone>+41 91 811 6921</phone>
      <email>chiara.zecca@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Claudio Gobbi, MD</last_name>
      <phone>+41 91 811 6921</phone>
      <email>claudio.gobbi@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Chiara Zecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Renard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Gobbi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Maino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosaria Sacco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alex Digesu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 23, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Cantonale, Bellinzona</investigator_affiliation>
    <investigator_full_name>Chiara Zecca</investigator_full_name>
    <investigator_title>Principal Investigator, Deputy Head of Multiple Sclerosis Center</investigator_title>
  </responsible_party>
  <keyword>overactive bladder</keyword>
  <keyword>posterior tibial nerve stimulation</keyword>
  <keyword>lower urinary tract symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

